Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc. sold a total of 193,328 shares of Eli Lilly & Co. common stock on June 17, 2024, at various prices.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold 193,328 shares of common stock on June 17, 2024.
• The sales were executed in multiple transactions at prices ranging from $882.00 to $892.14 per share.
• The weighted average prices for these transactions varied, with the lowest being $882.453 and the highest being $892.14.
• Following these transactions, Lilly Endowment Inc. still holds 97,583,810 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no indication of positive or negative sentiment. It is a routine filing.

Industry Context

This filing is a routine disclosure of stock sales by a major shareholder, which is common in the pharmaceutical industry. Such transactions are closely monitored by investors for insights into shareholder sentiment and potential market movements.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting insider transactions in publicly traded companies, including those in the pharmaceutical sector.
• The volume of shares sold by Lilly Endowment Inc. is significant but not unusual for a major shareholder.
• Comparable companies also have similar filings when major shareholders sell stock.

Stakeholder Impact

• The sale of shares by a major shareholder could potentially influence the stock price of Eli Lilly & Co., although the impact is likely to be minimal given the large number of shares outstanding.
• Shareholders may interpret this sale as a change in sentiment from a major holder.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, insider trading, Form 4, shareholder